Ultra-low-dose direct oral anticoagulants in vulnerable patients with atrial fibrillation or coronary artery disease
Open Access
- 30 April 2025
- journal article
- Published by Korean Society of Cardiovascular Disease Prevention in Cardiovascular Prevention and Pharmacotherapy
- Vol. 7 (2) , 38-43
Abstract
Direct oral anticoagulants (DOACs) have largely supplanted warfarin for stroke prevention in atrial fibrillation due to their superior safety and efficacy profiles. Although standard dosing regimens are well-established, lower doses—often referred to as ultra‐low-dose (ULD) DOACs—have been investigated in selected populations to balance thrombotic and bleeding risks. The concept of ULD DOACs was first introduced in the 2013 European Heart Rhythm Association Practical Guide specifically for post‐acute coronary syndrome patients with residual thrombotic risk. Clinical trials, including ATLAS ACS-TIMI 51 and COMPASS, demonstrated that rivaroxaban 2.5 mg twice a day reduced ischemic events when combined with aspirin, although this benefit was accompanied by an increased risk of major bleeding. Similarly, the ELDERCARE-AF trial revealed that edoxaban 15 mg once a day effectively prevented stroke in frail older patients. Conversely, evidence supporting ULDs of dabigatran and apixaban remains limited. Despite their potential benefits, inappropriate dose reductions based on subjective physician judgment rather than rigorous clinical guidelines may result in suboptimal anticoagulation and a heightened risk of thromboembolic events. This review explores the indications, supporting evidence, and potential risks associated with ULD DOACs, underscoring the need for well-designed studies to establish clear guidelines.Keywords
This publication has 30 references indexed in Scilit:
- Direct Oral Anticoagulant Dosing in Patients With Atrial FibrillationJACC: Asia, 2023
- Outcomes and Safety of Very-Low-Dose Edoxaban in Frail Patients With Atrial Fibrillation in the ELDERCARE-AF Randomized Clinical TrialJAMA Network Open, 2022
- Off-label dosing of non–vitamin K antagonist oral anticoagulants and clinical outcomes in Asian patients with atrial fibrillationHeart Rhythm, 2020
- Rivaroxaban: A Review for Secondary CV Prevention in CAD and PADDrugs, 2020
- Pattern and Impact of Off-label Underdosing of Non-Vitamin K Antagonist Oral Anticoagulants in Patients With Atrial Fibrillation Who are Indicated for Standard DosingThe American Journal of Cardiology, 2020
- Cardiovascular outcomes in patients with peripheral arterial disease as an initial or subsequent manifestation of atherosclerotic disease: Results from a Swedish nationwide studyJournal of Vascular Surgery, 2017
- Residual Ischemic Risk and Its Determinants in Patients With Previous Myocardial Infarction and Without Prior Stroke or TIA: Insights From the REACH RegistryClinical Cardiology, 2016
- Stent ThrombosisJACC: Cardiovascular Interventions, 2014
- Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trialThe Lancet, 2009
- Oral ximelagatran for secondary prophylaxis after myocardial infarction: the ESTEEM randomised controlled trialThe Lancet, 2003